LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
59 hedge funds and large institutions have $133M invested in LogicBio Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 6 reducing their positions, and 5 closing their positions.
333% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 6
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
36% more capital invested
Capital invested by funds: $97.5M → $133M (+$35.2M)
16% more funds holding
Funds holding: 51 → 59 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$13.4M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$6.01M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.18M |
| 4 |
SC
Samlyn Capital
New York
|
+$4.31M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JG
Jefferies Group
New York
|
-$308K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$288K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$250K |
| 4 |
JP Morgan Chase
New York
|
-$143K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$66.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RE
51
RBC Europe
London,
United Kingdom
| $2.1K | – | – | – |
|
|
MF
52
Manchester Financial
Westlake Village,
California
| $2K | – | – | – |
|
|
TFA
53
Toth Financial Advisory
Leesburg,
Virginia
| $2K | – | – | – |
|
|
ASN
54
Advisory Services Network
Atlanta,
Georgia
| $1K | -$3.35K | -500 | -86% |
|
|
IRC
55
Investors Research Corp
Atlanta,
Georgia
| $1K | – | – | – |
|
|
SBL
56
Sargent Bickham Lagudis
Boulder,
Colorado
| $1K | – | – | – |
|
|
WEC
57
Winslow Evans & Crocker
Boston,
Massachusetts
| $1K | +$1.18K | +176 | New |
|
|
AIG
58
American International Group
New York
| $73 | +$15K | +2,239 | +31% |
|
|
JG
59
Jefferies Group
New York
| – | -$308K | -33,948 | Closed |
|
|
60
Russell Investments Group
London,
United Kingdom
| – | -$250K | -27,598 | Closed |
|
|
FIA
61
FNY Investment Advisers
New York
| – | -$56K | -6,200 | Closed |
|
62
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$12K | -1,428 | Closed |
|
|
PFWA
63
Paces Ferry Wealth Advisors
Atlanta,
Georgia
| – | -$1K | -150 | Closed |
|
LOGC Hedge Fund Activity: Q4 2020 in Review
59 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q4 2020, worth a combined $133M — up 36% from $97.5M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new LOGC positions and 5 closed out — a net gain of 8 holders — while 26 added to existing stakes and 6 trimmed.
The largest buyer was OrbiMed, adding an estimated $13.4M. The largest seller was Jefferies Group, exiting entirely with an estimated $308K sold.
- 59 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q4 2020, up from 51 in Q3 2020.
- Funds reported $133M of LogicBio Therapeutics, Inc. Common Stock stock for Q4 2020, up 36% quarter-over-quarter.
- 13 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q4 2020 and 5 closed out, a net change of +8 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q4 2020 was OrbiMed, an estimated $13.4M added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q4 2020 was Jefferies Group, an estimated $308K sold.
Based on aggregated 13F filings for Q4 2020.